The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1700
April 15, 2024
View Complete Issue         Table of Contents 2019 
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
April 15, 2024 (Issue: 1700)
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
Article code: 1700a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.